FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* BORGESON JOHN A.						2. Issuer Name and Ticker or Trading Symbol Kodiak Sciences Inc. [KOD]									k all applic Directo	cable) or	ig Pers	10% Ov	vner	
(Last) (First) (Middle) 2631 HANOVER STREET					3. Date of Earliest Transaction (Month/Day/Year) 12/30/2019									X Officer (give title Other (specify below) See Remarks					, Постория	
(Street) PALO ALTO CA 94304 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)									. Indi ine) X	·					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						ar)	2A. Deemo Execution if any (Month/Da	Date	Code (Ins	Transaction Disposed Code (Instr. 5)		ties Acquir I Of (D) (Ins	ed (A) o tr. 3, 4 a	nd	5. Amour Securitie Beneficia Owned F	s ally following	Form (D) o	n: Direct r Indirect estr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	·	Amount	(A) or (D) Pr		е	Transact (Instr. 3 a	ion(s)			(111341. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Day if any (Month/Day/	ate, Tra	4. Transaction Code (Instr. 8)				6. Date Exer Expiration D (Month/Day/	ate		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		S	B. Price of Derivative Gecurity Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Co	ode	v	(A)	(D)	Date Exercisable		opiration	Title	Amour or Number of Shares	er						
Stock Option (Right to	\$73.51	12/30/2019			A		67,500		(1)	12	2/29/2029	Common Stock	67,50	0	\$0.00	67,50	0	D		

Explanation of Responses:

1. 1/48th of the shares subject to the option will vest on January 30, 2020, and 1/48th of the shares subject to the option vest on the same day of each month thereafter, subject to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) as of each such date.

Senior VP and Chief Financial Officer

/s/ Carlton Fleming, Attorneyin-Fact for John A. Borgeson

01/02/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of VICTOR PERLROTH, CARLTON FLEMING, DAVID PEINSIPP and KRIS S. TAMASHIRO, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or beneficial owner of more than 10% of a registered class of securities of KODIAK SCIENCES INC. (the "Company"), Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Forms 3, 4 or 5(including any amendments thereto) and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or Cooley LLP.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of September 24, 2019.

/s/ John A. Borgeson John A. Borgeson